What is Roth Capital's Estimate for Accuray Q1 Earnings?

Accuray Incorporated (NASDAQ:ARAY - Free Report) - Equities research analysts at Roth Capital issued their Q1 2026 earnings per share (EPS) estimates for Accuray in a research note issued on Thursday, May 1st. Roth Capital analyst J. Wittes forecasts that the medical equipment provider will post earnings of ($0.11) per share for the quarter. The consensus estimate for Accuray's current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray's Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.10) EPS and Q4 2026 earnings at ($0.11) EPS.

Separately, StockNews.com downgraded shares of Accuray from a "buy" rating to a "hold" rating in a research report on Monday.

Accuray Stock Performance

ARAY stock traded up $0.07 during trading hours on Friday, hitting $1.37. 410,712 shares of the stock were exchanged, compared to its average volume of 711,137. The company has a current ratio of 1.62, a quick ratio of 0.88 and a debt-to-equity ratio of 3.51. The firm has a market capitalization of $140.36 million, a P/E ratio of -27.30 and a beta of 1.30. Accuray has a 12 month low of $1.28 and a 12 month high of $2.95. The company has a 50-day simple moving average of $1.67 and a two-hundred day simple moving average of $1.92.

Accuray (NASDAQ:ARAY - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical equipment provider reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.04. The business had revenue of $113.24 million for the quarter, compared to analyst estimates of $101.53 million. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%.

Institutional Investors Weigh In On Accuray

Large investors have recently bought and sold shares of the company. Ameriprise Financial Inc. acquired a new position in shares of Accuray during the 4th quarter worth $35,000. Prudential Financial Inc. bought a new position in shares of Accuray in the fourth quarter worth about $43,000. ProShare Advisors LLC lifted its stake in Accuray by 50.7% in the 4th quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider's stock valued at $54,000 after purchasing an additional 9,187 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Accuray during the fourth quarter valued at about $66,000. Finally, SG Americas Securities LLC raised its position in shares of Accuray by 37.4% during the fourth quarter. SG Americas Securities LLC now owns 45,079 shares of the medical equipment provider's stock worth $89,000 after acquiring an additional 12,259 shares during the last quarter. 64.08% of the stock is currently owned by institutional investors and hedge funds.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.